InvestSMART

Chimeric Therapeutics Limited (ASX:CHM)

ALERT: Price-sensitive ASX Announcement for CHM
Current share price for CHM : $0.008 -0.027 (-77.14%)+
Announcement
Release
19 Aug 2026 9:08AM
Price at Release
$0.035
Full Release
download
Summary
Chimeric Therapeutics Limited has ceased enrolment in its Phase 1 trial for the CHM-2101 autologous CDH17 CAR-T cell therapy due to dose-limiting toxicities experienced by a second patient at dose level 3. The company's Safety Monitoring Committee determined this dose level as unsafe, leading to the halt of further enrolments. Despite the setbacks, anti-tumour activity was observed, suggesting CDH17 as a valid target for further development. Chimeric will focus on an in vivo delivery approach, which is expected to be faster and more cost-effective. The company has also implemented major cost reductions, anticipated to save approximately $4 million annually, and is negotiating with creditors to reduce liabilities. Ongoing discussions for additional funding have not yet resulted in any binding commitments. Chimeric's financial outlook indicates uncertainty regarding its ability to continue as a going concern without acquiring additional funding and successful creditor negotiations.
Key Points
  • Phase 1 trial enrolment halted due to dose-limiting toxicities at Dose Level 3.
  • Anti-tumour activity supports CDH17 as a valid target for development.
  • In vivo delivery approach to be pursued for CDH17.
  • Expected annual cost savings of approximately $4 million.
  • Uncertainty around future funding and financial stability.
  • Ongoing negotiations with creditors and potential funding sources.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.